Evaxion Biotech A/S (EVAX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Evaxion Biotech A/S (EVAX) trades at $3.41 with AI Score 66/100 (Grade B+). Evaxion Biotech A/S is a clinical-stage biotech company focused on developing artificial intelligence-driven immunotherapies for various diseases. Market cap: $21.54M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026EVAX stock analysis for 2026: Analysts have set a consensus price target of $10.00 for Evaxion Biotech A/S, suggesting 193.3% upside from the current price of $3.41. The AI MoonshotScore is 66/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
EVAX: 3/5 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Evaxion Biotech A/S (EVAX) Healthcare & Pipeline Overview
Evaxion Biotech A/S leverages artificial intelligence to develop innovative immunotherapies, targeting cancers and infectious diseases, positioning itself as a forward-thinking player in the biotechnology sector with a focus on cutting-edge treatments.
What Is the Investment Thesis for EVAX?
Evaxion Biotech A/S presents a compelling growth narrative driven by its innovative pipeline of AI-powered immunotherapies. The company's lead candidate, EVX-01, is currently in Phase IIb trials, with the potential to capture a significant share of the melanoma treatment market, valued at approximately $5 billion. Additionally, the ongoing development of EVX-02 and EVX-03 could further diversify revenue streams and enhance market presence. The company's unique AI-driven approach to drug development may lead to reduced timeframes in bringing products to market, a critical factor in the competitive biotech landscape. However, investors should be aware of risks associated with clinical trial outcomes and regulatory approvals, which could impact timelines and financial performance.
Based on FMP financials and quantitative analysis
EVAX Key Highlights
- Market Cap of $21.54M reflects early-stage development and growth potential.
- P/E ratio of 94.75 indicates high investor expectations for future earnings growth.
- Gross margin of 100.0% highlights the potential for high profitability upon commercialization.
- Profit margin of -129.6% signifies current investment in R&D and clinical trials.
- Beta of 0.27 suggests lower volatility compared to the broader market.
Who Are EVAX's Competitors?
EVAX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| NVS Novartis AG | $155.20 | -2.94% | $296.14B | 57 |
| REGN Regeneron Pharmaceuticals, Inc. | $645.84 | -1.29% | $66.54B | 91 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EVAX's Key Strengths?
- Innovative AI-driven approach to drug development.
- Strong pipeline with multiple candidates in various stages of clinical trials.
- Expertise in immunotherapy and vaccine development.
What Are EVAX's Weaknesses?
- Current lack of revenue due to clinical-stage status.
- High operational costs associated with R&D and clinical trials.
- Limited market presence compared to larger competitors.
What Could Drive EVAX Stock Higher?
- Results from Phase IIb trials of EVX-01 are anticipated in Q4 2026, which could significantly impact market perception and stock performance.
- Development of EVX-02 in Phase IIa trials is progressing, with updates expected in mid-2026.
- Pre-clinical development of vaccine candidates EVX-B1, EVX-B2, and EVX-V1 is ongoing, with potential for future partnerships.
What Are the Key Risks for EVAX?
- Financial-distress signal — its Altman Z-Score of -5.21 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-77.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial outcomes for EVX-01 and EVX-02 may not meet expectations, impacting future development plans.
- Regulatory hurdles and approval processes could delay product commercialization.
- Competition from established biotech firms could limit market share and pricing power.
What Are the Growth Opportunities for EVAX?
- Growth opportunity 1: Evaxion's lead candidate, EVX-01, is in Phase IIb trials for metastatic melanoma, a market expected to grow significantly due to increasing incidence rates. The melanoma treatment market is projected to reach $5 billion by 2027, providing substantial revenue potential for successful outcomes in clinical trials.
- Growth opportunity 2: The development of EVX-02 and EVX-03 expands Evaxion's portfolio in cancer immunotherapy, with the global cancer immunotherapy market anticipated to exceed $100 billion by 2025. Successful trials could position Evaxion as a key player in this lucrative segment.
- Growth opportunity 3: Evaxion's vaccine candidates, EVX-B1, EVX-B2, and EVX-V1, target bacterial and viral diseases, addressing a critical need in global health. The global vaccine market is expected to reach $100 billion by 2025, with increasing demand for innovative solutions.
- Growth opportunity 4: The integration of AI in drug development can significantly reduce time-to-market and R&D costs, providing a competitive edge. As AI technology continues to evolve, Evaxion's capabilities in this area may enhance its position in the biotechnology sector.
- Growth opportunity 5: Strategic partnerships and collaborations with larger pharmaceutical companies could facilitate access to additional resources and expertise, accelerating the development and commercialization of Evaxion's therapies.
What Opportunities Does EVAX Have?
- Growing demand for innovative cancer treatments and vaccines.
- Potential for strategic partnerships to enhance development capabilities.
- Expansion into new therapeutic areas and geographic markets.
What Threats Does EVAX Face?
- Regulatory challenges and uncertainties in clinical trial outcomes.
- Intense competition from established biotech and pharmaceutical companies.
- Market volatility and funding challenges for clinical-stage companies.
What Are EVAX's Competitive Advantages?
- Unique AI-driven approach to immunotherapy development, differentiating Evaxion from competitors.
- Strong pipeline of innovative therapies targeting high-value markets.
- Expertise in both biotechnology and artificial intelligence, enhancing R&D capabilities.
What Does EVAX Do?
Evaxion Biotech A/S, founded in 2008 and headquartered in Hørsholm, Denmark, is a clinical-stage biotechnology company dedicated to developing artificial intelligence-powered immunotherapies. The company aims to address significant unmet medical needs in the treatment of cancers, bacterial diseases, and viral infections. Evaxion's innovative approach utilizes advanced AI algorithms to identify and develop novel therapeutic candidates, enhancing the efficiency and effectiveness of drug discovery. The company's flagship products include EVX-01, currently in Phase IIb clinical trials for metastatic melanoma, and EVX-02, which is in Phase IIa trials for adjuvant melanoma. Additionally, EVX-03 is a DNA-based immunotherapy aimed at treating various cancers. Beyond oncology, Evaxion is also advancing vaccine candidates EVX-B1, EVX-B2, and EVX-V1, which are in pre-clinical stages targeting bacterial and viral diseases. With a small team of 46 employees, Evaxion is positioned to capitalize on the growing demand for innovative treatments in the healthcare sector, particularly those that harness the power of artificial intelligence.
What Products and Services Does EVAX Offer?
- Develop artificial intelligence-powered immunotherapies for cancer and infectious diseases.
- Conduct clinical trials for innovative cancer treatments, including EVX-01 and EVX-02.
- Advance pre-clinical vaccine candidates targeting bacterial and viral infections.
- Leverage AI technology to enhance drug discovery and development processes.
- Focus on addressing unmet medical needs in oncology and infectious disease sectors.
How Does EVAX Make Money?
- Revenue generation primarily through the successful commercialization of therapeutics.
- Funding through partnerships, grants, and potential licensing agreements.
- Investment in R&D to develop innovative treatments with high market potential.
- Engagement in clinical trials to validate product efficacy and safety.
What Industry Does EVAX Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in technology and increasing demand for innovative therapies. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, with significant contributions from cancer immunotherapy and vaccine development. Evaxion Biotech A/S operates within this dynamic landscape, focusing on AI-driven solutions that differentiate it from traditional approaches. The competitive landscape includes established players and emerging companies, with a growing emphasis on precision medicine and personalized therapies.
Who Are EVAX's Key Customers?
- Healthcare providers and hospitals seeking advanced treatment options.
- Pharmaceutical companies interested in licensing innovative technologies.
- Patients with unmet medical needs in cancer and infectious diseases.
Company Profile
Evaxion Biotech A/S operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Horsholm, DK. The company is led by CEO Helen Katrina Tayton-Martin. EVAX has traded publicly since 2021.
F-Score 3/9Financial Health
Evaxion Biotech A/S's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.21 places it in the distress zone, a signal of elevated financial risk.
ROE -78%Key Financial Metrics
Return on equity for Evaxion Biotech A/S stands at -77.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -34.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.85 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -36.6%, the inverse of the P/E and a quick read on earnings relative to price.
EVAX Valuation & Market Position
With a $21.54M market cap, Evaxion Biotech A/S sits in the micro-cap segment of the market. Relative to its peer group, EVAX's quantitative score of 66/100 is below the peer average of 79/100.
FY2026 estForward Outlook
Wall Street analysts project Evaxion Biotech A/S revenue of about $5.3M for fiscal 2026, with EPS near $-0.03.
EVAX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Evaxion's recent insider buying suggests those in the know see long-term value, mirroring situations like Palantir's early days where insider confidence fueled growth.
- The buzz in the community is hopeful about their pipeline, especially the personalized cancer immunotherapy, reminiscent of early CAR-T therapy excitement.
- Positive sentiment is building around potential partnerships, similar to how BioNTech's collaboration with Pfizer validated their mRNA technology.
- Evaxion's focus on AI-driven drug discovery is attracting attention, echoing the hype around Recursion Pharmaceuticals' approach to drug development.
Bear Case
- Community skepticism exists regarding the timeline for clinical trial results, similar to concerns surrounding Cassava Sciences' Alzheimer's drug.
- Recent market volatility has made investors wary of biotech stocks, reminiscent of the dot-com bubble burst affecting internet companies.
- There's a general concern about funding for biotech companies, especially those without approved products, mirroring the challenges faced by many startups after the 2008 financial crisis.
- Some community members are worried about competition in the cancer immunotherapy space, similar to the crowded electric vehicle market where many companies are vying for dominance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
EVAX Latest News
-
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
GlobeNewswire · Jul 1, 2026
-
European Equities Traded in the US as American Depositary Receipts Decline Friday
MT Newswires · Jun 26, 2026
-
Evaxion receives Prix Galien UK Award for Best digital health solution
GlobeNewswire · Jun 12, 2026
-
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
GlobeNewswire · Jun 11, 2026
EVAX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EVAX.
Price Targets
Consensus target: $10.00
EVAX MoonshotScore
What does this score mean?
The MoonshotScore rates EVAX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
European Equities Traded in the US as American Depositary Receipts Decline Friday
Evaxion receives Prix Galien UK Award for Best digital health solution
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
Leadership: Helen Katrina Tayton-Martin
CEO
Helen Katrina Tayton-Martin has extensive experience in the biotechnology sector, with a strong background in research and development. She holds advanced degrees in life sciences and has held various leadership roles in biotech companies prior to joining Evaxion. Her expertise spans across drug development, strategic planning, and operational management.
Track Record: Under her leadership, Evaxion has advanced its clinical programs and strengthened its focus on AI-driven immunotherapy development. Tayton-Martin has successfully guided the company through critical funding rounds and strategic partnerships, positioning it for future growth.
Evaxion Biotech A/S ADR Information Sponsored
An American Depositary Receipt (ADR) represents shares in a foreign company traded on U.S. exchanges. Evaxion Biotech A/S's ADR allows U.S. investors to access its shares while providing the benefits of U.S. market regulations.
- Home Market Ticker: NASDAQ, United States
- ADR Level: 2
- ADR Ratio: 1:1
Common Questions About EVAX (Healthcare)
What does Evaxion Biotech A/S do?
Evaxion Biotech A/S is a clinical-stage biotechnology company focused on developing artificial intelligence-powered immunotherapies for treating cancers, bacterial diseases, and viral infections. The company's key products include EVX-01, EVX-02, and EVX-03, which are in various stages of clinical trials, alongside several pre-clinical vaccine candidates.
What are the main risks for EVAX?
Evaxion Biotech A/S faces several risks, including the potential failure of clinical trials for its lead candidates, EVX-01 and EVX-02, which could hinder future development and commercialization efforts. Regulatory challenges may also arise, affecting approval timelines. Additionally, competition from larger biotech firms poses a threat to market share and pricing strategies.
How does Evaxion Biotech A/S manage patent expiration risks?
Evaxion Biotech A/S actively engages in patent filing and lifecycle management to protect its intellectual property. The company focuses on developing novel therapies that can extend patent protection and reduce exposure to biosimilar competition. Additionally, ongoing research and development efforts aim to create new products that can continue to drive revenue post-patent expiration.
What are the key factors to evaluate for EVAX?
Evaxion Biotech A/S (EVAX) holds an AI score of 66/100 (moderate). Analysts target $10.00 (+193%). Not financial advice.
How frequently does EVAX data refresh on this page?
EVAX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EVAX's recent stock price performance?
Evaxion Biotech A/S (EVAX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative AI-driven approach to drug development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EVAX overvalued or undervalued right now?
Valuing Evaxion Biotech A/S (EVAX) requires multiple metrics. Analysts target $10.00 (+193%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying EVAX?
Before investing in Evaxion Biotech A/S (EVAX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information and may be subject to change.